ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cellsAnti-tumor T cells, NK cells...
Dr. Wakelee is a world-renowned expert in the research and treatment of lung cancerOncoC4's SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and...
The Phase 1/2 trial will assess the efficacy and safety of BNT316/ONC-392 in combination with the radioligand therapy lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with metastatic...
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (œOncoC4), a late-stage biopharmaceutical company developing novel medicines for cancer, today announced its participation in the 42nd...
ROCKVILLE, Md., Sept. 28, 2023 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced the appointment of Abid Ansari as Chief...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
March 20 (Reuters) - Germany's BioNTech SE (22UAy.DE) said on Monday that it signed a deal with privately held OncoC4 Inc to co-develop and commercialize its cancer antibody drug candidate.
ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer (PROC) (PRESERVE-004, NCT05446298).